- Home
- GNTA vs CBUS Comparison
GNTA vs CBUS Comparison
Compare GNTA & CBUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | CBUS |
|---|---|---|
| Founded | 2014 | 2010 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.7M | 69.9M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | GNTA | CBUS |
|---|---|---|
| Price | $1.61 | $1.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 100.5K | ★ 168.2K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,794,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $109.96 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.35 | $1.09 |
| 52 Week High | $10.00 | $4.24 |
Technical Indicators
Market Signals| Indicator | GNTA | CBUS |
|---|---|---|
| Relative Strength Index (RSI) | 30.36 | 57.01 |
| Support Level | $1.80 | $1.50 |
| Resistance Level | $2.07 | $1.75 |
| Average True Range (ATR) | 0.18 | 0.14 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 0.00 | 69.23 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.